Publications by authors named "David Whitman"

Claim this Profile
A
Amide- and bis-amide-linked highly potent and broadly active antifungal agents for the treatment of invasive fungal infections- towards the discovery of pre-clinical development candidate FC12406.
Simon D P Baugh, Anna Chaly, Damian G Weaver, David B Whitman, Jeffrey C Pelletier

Med Chem Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Affecting Microbial Inactivation during High Pressure Processing in Juices and Beverages: A Review.
Richard Podolak, David Whitman, Darryl Glenn Black

J Food Prot· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Paul J Coleman, John D Schreier, Christopher D Cox, Michael J Breslin, David B Whitman

ChemMedChem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Christopher D Cox, Michael J Breslin, David B Whitman, John D Schreier, Georgia B McGaughey

J Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
David B Whitman, Christopher D Cox, Michael J Breslin, Karen M Brashear, John D Schreier

ChemMedChem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.
Christopher D Cox, Georgia B McGaughey, Michael J Bogusky, David B Whitman, Richard G Ball

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Christopher D Cox, Paul J Coleman, Michael J Breslin, David B Whitman, Robert M Garbaccio

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Christopher D Cox, Michael J Breslin, David B Whitman, Paul J Coleman, Robert M Garbaccio

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP.
Christopher D Cox, Maricel Torrent, Michael J Breslin, Brenda J Mariano, David B Whitman

Bioorg Med Chem Lett· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.
David B Whitman, Ben C Askew, Le T Duong, Carmen Fernandez-Metzler, Wasyl Halczenko

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
Paul J Coleman, Ben C Askew, John H Hutchinson, David B Whitman, James J Perkins

Bioorg Med Chem Lett· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Environment. Floating pharmacy.
David Whitman

US News World Rep· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Robert S Meissner, James J Perkins, Le T Duong, George D Hartman, William F Hoffman, David B Whitman

Bioorg Med Chem Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new power of labels in the abortion wars.
David Whitman

US News World Rep· July 1990

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis